Clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia: A YACHT multicenter retrospective study

Publication date: Available online 31 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Takayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, Satomi Ito, Takuya Miyazaki, Yoshimi Ishii, Eriko Ogusa, Hideyuki Koharazawa, Hiroyuki Takahashi, Kenji Motohashi, Jun Aoki, Yuki Nakajima, Kenji Matsumoto, Maki Hagihara, Chizuko Hashimoto, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima A multicenter retrospective analysis was performed to evaluate the clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia. The study cohort included 305 patients who were newly diagnosed with AML from 2000 to 2015 and received standard induction chemotherapy. Transplantation was performed in 168 patients. The median ferritin value was 512 ng/mL (range: 8–9,475). Ferritin correlated with lactate dehydrogenase, C-reactive protein, white blood cell count, and blast count, and elevation of ferritin was associated with poor performance status. The median follow-up period was 58 months (range: 4–187) among survivors. The high ferritin group (≥400 ng/mL) demonstrated inferior event-free survival (EFS) at the 5-year interval (30% vs. 40%, P = 0.033) compared to the low ferritin group. Multivariate analysis in the high-risk karyotype revealed that high ferritin levels predicted worse EFS (HR = 2.07, 95% CI: 1.28–3.33, P = 0.003). Elevated ferritin at diagnosis may indicate tumo...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research